Working to facilitate rapid translation of scientific discoveries into therapeutics

Hsin-Wei Chen

Hsin-Wei Chen, PhD

Hsin-Wei Chen received his PhD in Agricultural Chemistry from the National Taiwan University; he is currently an associate investigator in the National Institute of Infectious Diseases and Vaccinology at the National Health Research Institutes. Over the last six years, Hsin-Wei has focused his scientific interests on the dengue vaccine development and immune regulation. His team has developed a novel platform to express high levels of recombinant lipoproteins with intrinsic adjuvant properties using an Escherichia coli-based system. Most important, they developed recombinant lipidated dengue subunit vaccine candidates. These candidates independently stimulate long-lasting neutralizing antibodies against dengue virus and reduce the risk of antibody-dependent enhancement. In addition, Hsin-Wei and his group was the first team identifying a distinct CD8+ T cells subset, which secretes IL-17 but has little cytotoxic activity. They named this subset T noncytotoxic-17 (Tnc17). To maintain a comparative convention with cytotoxic T lymphocytes, Tc1 or Tc2, these IL-17- producing CD8+ T cells are now ermed Tc17 cells. A significant increase in the number of Tc17 was found in tumors, their role and interaction with other cell types remain unclear. Hsin-Wei and his group demonstrate that the presence of CD4+CD25+ (regulatory T cells), but not the CD4+CD25- T cell population, maintain the survival and expansion of Tc17 cells. These results correlate closely with enrichment of Tc17 and regulatory T cells in cancer patients. Their findings open new avenues for understanding the regulation of Tc17 cell development and tumor escape mechanisms.

2013-2021©European Society for Translational Medicine (EUSTM)